EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling

Sjoerd J F Hermans iD, Yvette van Norden, Jurjen Versluis iD, Anita W Rijneveld iD, Bronno van der Holt iD, Okke de Weerdt, Bart J Biemond iD, Arjan A van de Loosdrecht iD, Lotte E van der Wagen, Mar Bellido iD, Michel van Gelder iD, Walter J F M van der Velden iD und 7 weitere

Cancer Medicine · 2024-05 · 13 (9)

DOI: 10.1002/cam4.6756 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Medicine, online erschienen am 29.04.2024. Verfasst von Sjoerd J F Hermans und 18 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Clofarabine, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We recently reported results of the prospective, open‐label HOVON‐100 trial in 334 adult patients with acute lymphoblastic leukemia (ALL) randomized to first‐line treatment with or without clofarabine (CLO). No improvement of event‐free survival (EFS) was observed, while a higher proportion of patients receiving CLO obtained minimal residual disease (MRD) negativity.

Aim

In order to investigate the effects of CLO in more depth, two multi‐state models were developed to identify why CLO did not show a long‐term survival benefit despite more MRD‐negativity.

Methods

The first model evaluated the effect of CLO on going off‐protocol (not due to refractory disease/relapse, completion or death) as a proxy of severe treatment‐related toxicity, while the second model evaluated the effect of CLO on obtaining MRD negativity. The subsequent impact of these intermediate events on death or relapsed/refractory disease was assessed in both models.

Results

Overall, patients receiving CLO went off‐protocol more frequently than control patients (35/168 [21%] vs. 18/166 [11%], p = 0.019; HR 2.00 [1.13–3.52], p = 0.02), especially during maintenance (13/44 [30%] vs. 6/56 [11%]; HR 2.85 [95%CI 1.08–7.50], p = 0.035). Going off‐protocol was, however, not associated with more relapse or death. Patients in the CLO arm showed a trend towards an increased rate of MRD‐negativity compared with control patients (HR MRD‐negativity: 1.35 [0.95–1.91], p = 0.10), which did not translate into a significant survival benefit.

Conclusion

We conclude that the intermediate states, i.e., going off‐protocol and MRD‐negativity, were affected by adding CLO, but these transitions were not associated with subsequent survival estimates, suggesting relatively modest antileukemic activity in ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClofarabinePrecursor Cell Lymphoblastic Leukemia-LymphomaNeoplasm, ResidualHumansAdultMaleFemaleMiddle AgedProspective StudiesYoung AdultRisk AssessmentAdolescentAntineoplastic Combined Chemotherapy ProtocolsAged

Stichwörter der Autor:innen

MRDacute lymphoblastic leukemiaclofarabinemulti‐state modelingoff‐protocol treatmenttransition probability

Substanzen

Clofarabine

Autor:innen und Institutionen

  • Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands.
  • HOVON Foundation, Rotterdam, The Netherlands.
  • Department of Hematology, Sint Antonius Hospital, Nieuwegein, The Netherlands.
  • Department of Hematology, Amsterdam University Medical Centers, Amsterdam Medical Center, Amsterdam, The Netherlands.
  • Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands.
  • Department of Hematology, University Medical Center, Utrecht, The Netherlands.

ORCID-Profile: Sjoerd J F Hermans, Jurjen Versluis, Anita W Rijneveld, Bronno van der Holt, Bart J Biemond, Arjan A van de Loosdrecht, Mar Bellido, Michel van Gelder, Walter J F M van der Velden, Vincent H J van der Velden, Liesbeth C de Wreede, Douwe Postmus, Francesco Pignatti, Jan J Cornelissen

Zitieren

APA

Hermans, S. J. F., van Norden, Y., Versluis, J., Rijneveld, A. W., van der Holt, B., de Weerdt, O., Biemond, B. J., van de Loosdrecht, A. A., van der Wagen, L. E., Bellido, M., van Gelder, M., van der Velden, W. J. F. M., Selleslag, D., van Lammeren-Venema, D., van der Velden, V. H. J., de Wreede, L. C., Postmus, D., Pignatti, F., & Cornelissen, J. J. (2024). Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling. Cancer Medicine, 13(9). https://doi.org/10.1002/cam4.6756

Vancouver

Hermans SJF, van Norden Y, Versluis J, Rijneveld AW, van der Holt B, de Weerdt O, et al. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling. Cancer Medicine. 2024;13(9). doi:10.1002/cam4.6756

BibTeX
@article{Hermans2024,
  author = {Hermans, Sjoerd J F and van Norden, Yvette and Versluis, Jurjen and Rijneveld, Anita W and van der Holt, Bronno and de Weerdt, Okke and Biemond, Bart J and van de Loosdrecht, Arjan A and van der Wagen, Lotte E and Bellido, Mar and van Gelder, Michel and van der Velden, Walter J F M and Selleslag, Dominik and van Lammeren-Venema, Daniëlle and van der Velden, Vincent H J and de Wreede, Liesbeth C and Postmus, Douwe and Pignatti, Francesco and Cornelissen, Jan J},
  title = {Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {9},
  doi = {10.1002/cam4.6756}
}
Kostenlos starten →